Sick-Day Rules for GLP-1 Microdosing: What to Know When a Stomach Bug, Flu, or Fever Lands on Injection Week

A woman on a low weekly dose of tirzepatide wakes on a Sunday with a fever of 39 degrees and a stomach that will not hold water. Sunday is injection day. She has three questions and no one to ask before Monday: does she inject, does she wait, and if she waits, how late is too late? By Tuesday she has kept down two cups of tea and half a banana, is dizzy when she stands, and has a fourth question, which is whether the dizziness is the bug or the drug.

None of those questions has a trial answer, because no GLP-1 trial has randomised people to inject or skip while ill. But each has a well-documented framework. The prescribing information for every semaglutide and tirzepatide product gives a window for a late dose. Sick-day medication guides from several national health systems, written for people with diabetes and kidney disease, have a category for dehydrating illness and a list of medicines to hold during it. The labels themselves carry a warning about acute kidney injury in people who became dehydrated on the drug. And the physiology of fever, vomiting, and diarrhoea gives real numbers for the fluid a sick person is losing.

This article lays those frameworks side by side: what the labels say about timing, why the sick-day guides mention GLP-1 receptor agonists at all, what a missed week does to the drug level, how much fluid a fever and a stomach bug actually cost, what oral rehydration solution does that water cannot, why a week on the sofa threatens muscle, and which of these decisions belong to the prescriber rather than the patient.

What do the semaglutide and tirzepatide labels say about a delayed dose?

The labels give a specific window for taking a late dose and say to skip it once that window closes. The Ozempic prescribing information states that a missed dose should be administered as soon as possible within five days, and that if more than five days have passed the dose should be skipped and the next dose given on the regularly scheduled day. The Wegovy label phrases the same rule differently: take the missed dose if the next scheduled dose is more than 48 hours away, and skip it if the next dose is less than 48 hours away. Seven days minus two is five, so the two semaglutide labels agree. For tirzepatide, the Mounjaro and Zepbound labels give four days, or 96 hours, after which the dose is skipped.

The labels also say something about longer gaps. The Wegovy label states that if more than two consecutive doses are missed, dosing can be resumed as scheduled or, if the prescriber judges it necessary, the medication can be reinitiated and the escalation schedule followed again. That guidance exists because someone returning to a 2.4 mg dose after three weeks off has lost the gastrointestinal adaptation that the escalation built. For someone on a microdose at or below the 0.25 mg starting dose, there is no lower rung to return to, and the practical question is simply whether to restart at the same dose; that question still goes to the prescriber, because the person restarting may also still be recovering from the illness that caused the gap.

What the labels do not do is tell anyone whether to inject while sick. They describe timing rules for a dose that was missed for any reason. The decision about whether illness is a reason to miss one comes from a different set of documents.

Why do sick-day medication guides mention GLP-1 receptor agonists?

Sick-day guides mention GLP-1 receptor agonists because of the kidney. Sick-day rules are a concept from diabetes and kidney care: during an illness that causes vomiting, diarrhoea, or fever with sweats, certain medicines that are safe when a person is well become risky when they are dehydrated, and the guides list which ones to hold until the person is eating and drinking normally again for 24 to 48 hours. The core list, remembered in Canada by the acronym SADMANS, covers sulfonylureas, ACE inhibitors, diuretics, metformin, angiotensin receptor blockers, NSAIDs, and SGLT2 inhibitors. Scotland's Medicine Sick Day Rules card and the English Think Kidneys programme use a similar list. Several more recent national guides, including Australian diabetes society advice, add GLP-1 receptor agonists, with the note that they should be considered for withholding when a person is vomiting or cannot keep fluids down.

The reasoning traces back to the labels. The Ozempic and Wegovy prescribing information both carry a warning on acute kidney injury: there have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, some requiring haemodialysis, in people taking semaglutide, some of them with no known kidney disease beforehand. The label states that a majority of these events occurred in people who had experienced nausea, vomiting, diarrhoea, or dehydration. The mechanism is not the drug acting on the kidney directly; it is the drug contributing to fluid loss, and fluid loss reducing kidney perfusion. An illness that produces the same fluid loss independently doubles up on the same pathway.

The scale of the medication's own contribution is visible in trial data. In STEP 1, 44 percent of participants on semaglutide 2.4 mg reported nausea against 16 percent on placebo, 32 percent reported diarrhoea against 16 percent, and 25 percent reported vomiting against 7 percent. A microdose sits far below 2.4 mg, and these events rise with dose, so the medication's share of the problem is smaller at low doses. But a smaller share is not zero, and a person whose gut is already emptying more slowly and whose thirst signal is already blunted has less margin when a virus arrives.

How far does the drug level fall if a GLP-1 dose is missed during illness?

One missed weekly dose takes semaglutide to about half its usual trough, and the level recovers within two to three injections of restarting. The chart below models this with a one-compartment model and semaglutide's seven-day half-life. At steady state, the level runs from about 112 percent of the weekly average two days after each injection down to about 80 percent just before the next one. When the day 7 dose is missed, the decline simply continues: about 60 percent by day 10, which is the outer edge of the five-day window, and about 40 percent by day 14. Tirzepatide, with a five-day half-life, falls faster, to about 48 percent at day 10 and 28 percent at day 14.

Two things in that second week are predictable. Appetite comes back, often noticeably, because the level has dropped below anything the person has felt since their first weeks on the medication. That is pharmacology, not failure, and it often coincides with the return of appetite that recovery from illness brings anyway. And the medication's own gastrointestinal effects fade, which for someone still nauseated from a virus is not unwelcome. When dosing resumes on day 14, the model puts the first post-restart peak at about 80 percent of the average rather than 112, the second at about 96 percent, and the third back at the usual level. There is no rebound above baseline and no reason in the kinetics to take a larger dose to catch up; the labels do not describe any such thing.

Why does being sick on a GLP-1 medication make eating so much harder?

Because the body already uses GLP-1 as part of its sickness response, and the medication adds to a brake that is already on. Loss of appetite during infection is one of the oldest and most conserved features of the immune response. Cytokines released by immune cells, chiefly interleukin-1 beta, interleukin-6, and tumour necrosis factor alpha, act on the hypothalamus to suppress hunger and on the stomach to slow emptying. The gut joins in. Kahles and colleagues reported in Diabetes in 2014 that circulating GLP-1 rises sharply in critically ill patients and tracks inflammatory markers, and that giving healthy volunteers a low dose of bacterial endotoxin raised their GLP-1 too. Lebrun and colleagues showed in Cell Reports in 2017 that intestinal L cells, the cells that make GLP-1, sense bacterial lipopolysaccharide directly and respond by releasing the hormone.

The result on a sick day is three inputs pointing the same way: the cytokine signal, the body's own inflammatory GLP-1, and the injected agonist. Food that was already unappealing becomes actively unpleasant, and the morning coffee and toast that were keeping protein intake alive disappear. The nausea question compounds it. Nausea from a virus and nausea from the medication feel identical, so a person cannot tell which one they are having, and neither can the prescriber over the phone. This is a further argument for the prescriber to know about the illness before the next injection rather than after: a dose given into an already nauseated gut produces a data point nobody can interpret.

Fluid follows the same logic. GLP-1 receptor agonists blunt thirst in animal studies and, by most accounts, in people, and a person who has stopped noticing thirst in week ten of a protocol does not suddenly start noticing it during a fever. Thirst is an unreliable guide for anyone with gastroenteritis; on a GLP-1 medication it is worse than unreliable. The replacement has to be scheduled rather than felt.

How much extra fluid does a fever or a stomach bug actually cost?

A fever of 39.5°C costs roughly an extra half litre a day; a day of gastroenteritis can cost an extra litre and a half. The baseline is about 2.5 litres of water lost daily by a healthy adult: around 1.5 litres as urine, 800 to 900 millilitres as insensible loss through skin and breath, and about 100 millilitres in stool. Standard clinical estimates put the rise in insensible loss at 10 to 13 percent of total daily fluid requirement for each degree Celsius above normal, which for a 2.5°C fever is 500 to 600 millilitres. A loose stool carries roughly 200 millilitres, and an episode of vomiting 100 to 200. Six stools and three vomits, an ordinary day with a norovirus, is 1.2 litres plus another 450, on top of the baseline.

The kidney compensates by concentrating urine, which is why urine output in the gastroenteritis bar below is drawn lower, and why urine colour and frequency are the simplest home check. Pale urine passed at least every six to eight hours means replacement is roughly keeping up. Dark urine, or none for eight hours, means it is not. Dizziness on standing, a racing pulse at rest, and a dry mouth that water does not fix are the next signs, and they are the point at which the labels' language about dehydration requiring medical attention applies.

What does oral rehydration solution do that water and sports drinks do not?

Oral rehydration solution replaces the sodium that leaves with stool and vomit, and it uses a precise glucose-to-sodium ratio to pull water across the gut wall. Water replaces volume only, and a person who drinks two litres of plain water to replace two litres of diarrhoea ends up with the right volume and too little sodium, which is its own route to dizziness and confusion. The World Health Organization's reduced-osmolarity formula contains 75 millimoles per litre of sodium, 75 millimoles per litre of glucose (13.5 grams), 20 of potassium, and citrate, at an osmolarity of 245 milliosmoles per litre. That glucose level is not there for energy; it is there because the intestinal sodium-glucose co-transporter moves sodium and water into the body most efficiently when glucose is present in roughly equal molar amounts.

Sports drinks and fruit juice fail on both counts. A typical sports drink has about 20 millimoles per litre of sodium, a quarter of the ORS figure, and around 60 grams per litre of sugar, more than four times the ORS figure. Apple juice has almost no sodium and about 110 grams per litre of sugar. Large sugar loads are osmotically active in the bowel and can pull water into the gut, worsening diarrhoea. The comparison below puts the numbers side by side.

Two points are specific to the GLP-1 setting. Gastric emptying is slower on the medication, more so early in a protocol and less so after weeks of steady exposure, and a stomach that empties slowly and is already nauseated will return a large gulp faster than a small one; the standard paediatric advice of small volumes every few minutes applies to adults on these medications with unusual force. And oral medicines of any kind, including anti-nausea tablets, may sit in a slow, vomiting stomach without being absorbed, which is one reason prescribers sometimes reach for a dissolving or non-oral form.

Does a week in bed on a GLP-1 medication cost lean mass?

A week in bed costs lean mass in anyone, at a rate the bed-rest literature has measured precisely, and a GLP-1 medication makes the protein needed to limit the loss harder to eat. Dirks and colleagues, publishing in Diabetes in 2016, put healthy men in their twenties through seven days of strict bed rest and measured a 1.4 kilogram fall in lean tissue mass, a 3.2 percent drop in thigh muscle cross-sectional area, and a 29 percent fall in insulin sensitivity. Kortebein and colleagues, in JAMA in 2007, kept healthy adults with a mean age of 67 in bed for ten days and recorded a 1.5 kilogram whole-body lean mass loss, 0.95 kilograms of it from the legs, alongside a 16 percent fall in knee extensor strength. Those participants were eating a controlled, adequate diet.

A person with a fever, a virus-suppressed appetite, and a GLP-1 medication on board is usually not. Protein intake on a sick day often falls to a fraction of the 1.2 to 1.6 grams per kilogram that most protocols aim for, at the same moment the muscle is most vulnerable. The European Society for Clinical Nutrition and Metabolism recommends 1.2 to 1.5 grams per kilogram for older adults during acute illness, above the 1.0 to 1.2 it recommends when they are well, precisely because illness accelerates loss. Most of what bed rest takes is regained once activity resumes, but the recovery is measured in weeks, and the person who loses 1.4 kilograms in a week does not get it back in the following one.

The practical corollary is that protein is the one thing a sick person on a GLP-1 protocol can still control. Solid food may be out of the question; milk, yoghurt, eggs, a protein shake, or broth with something dissolved in it are usually not. Thirty grams across a day is far better than zero, and once the fever breaks, a walk to the end of the street signals the muscle that it is still needed.

Which sick-day situations call for a prescriber, and which call for urgent care?

A cold without gut symptoms calls for nobody; vomiting or diarrhoea calls for the prescriber the same day; and inability to keep fluids down for 24 hours, no urine for eight, dizziness on standing, or severe abdominal pain call for urgent care. The table below organises the frameworks from the earlier sections by scenario. The middle column reports what the labels and sick-day guides actually say; it is not an instruction to hold or take a dose, which remains the prescriber's decision. The severe abdominal pain row exists because the semaglutide and tirzepatide labels carry warnings for acute pancreatitis and acute gallbladder disease, both of which present with abdominal pain and can be mistaken for a bad stomach bug.

What should the conversation with the prescriber cover?

The conversation should establish, before anyone is sick, what the prescriber wants done when injection day falls inside an illness, because the question always arrives on a weekend. Most prescribers who write for GLP-1 medications have a standing answer, and asking for it at a routine visit turns a Sunday-morning guess into a plan. The useful questions are concrete: whether a fever alone changes anything, whether vomiting means the dose waits, how many days of normal eating they want to see before restarting, and whether restarting is at the same dose. The pharmacist has a role too, on the two over-the-counter categories that matter, NSAIDs and anti-diarrhoeals, and on whether any regular oral medicine needs a different form while vomiting continues.

During the illness itself, the prescriber needs three facts to make a decision: how long the vomiting or diarrhoea has lasted, whether fluids are staying down, and when the last urine was. Those three answers separate a stomach bug being managed at home from dehydration that needs a clinic. A person who arrives with them, and with the label's five-day or four-day window in mind, gets a clear answer quickly. A person who has already injected into a nauseated gut, or skipped three weeks and restarted alone, presents the prescriber with a picture they cannot read.

The labels set the window. The sick-day guides name the risk. The physiology sets the fluid bill.

Illness on a GLP-1 protocol is a question with no trial behind it and a great deal of documentation around it. The labels allow a late dose within five days for semaglutide and four for tirzepatide, and say to skip it after that. The sick-day guides list GLP-1 receptor agonists during vomiting because the labels themselves warn of kidney injury in people who became dehydrated. A missed week takes the drug level to about 40 percent of average, brings appetite back, and is repaired within two or three injections of restarting. A fever costs half a litre a day and a stomach bug a litre and a half, replaced most efficiently with oral rehydration solution in small volumes, and a week in bed costs more than a kilogram of muscle that only protein and movement bring back. Every one of those facts is worth knowing before the fever arrives. The decision about the injection is worth handing to the prescriber before it does.

Frequently asked questions

Clinical references

1. Novo Nordisk. Ozempic (semaglutide) injection: prescribing information, dosage and administration (missed dose) and warnings and precautions (acute kidney injury, acute pancreatitis, acute gallbladder disease). US Food and Drug Administration; 2017, with subsequent revisions.
2. Novo Nordisk. Wegovy (semaglutide) injection 2.4 mg: prescribing information, dosage and administration (missed dose, missed consecutive doses) and warnings and precautions. US Food and Drug Administration; 2021, with subsequent revisions.
3. Eli Lilly. Mounjaro (tirzepatide) injection: prescribing information, dosage and administration (missed dose) and warnings and precautions. US Food and Drug Administration; 2022, with subsequent revisions.
4. Eli Lilly. Zepbound (tirzepatide) injection: prescribing information. US Food and Drug Administration; 2023, with subsequent revisions.
5. Diabetes Canada Clinical Practice Guidelines Expert Committee. Appendix 8: Sick-day medication list (SADMANS). Canadian Journal of Diabetes. 2018;42(Suppl 1):S316.
6. NHS Scotland, Scottish Patient Safety Programme. Medicine Sick Day Rules card. Healthcare Improvement Scotland; 2015, with subsequent revisions.
7. Think Kidneys (NHS England and UK Renal Registry). Sick day guidance in patients at risk of acute kidney injury: a position statement. 2018.
8. Australian Diabetes Society. Sick day management for adults with type 2 diabetes: guidance on glucose-lowering medications during acute illness. 2020, with subsequent revisions.
9. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
10. Kahles F, Meyer C, Möllmann J, et al. GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering. Diabetes. 2014;63(10):3221-3229.
11. Lebrun LJ, Lenaerts K, Kiers D, et al. Enteroendocrine L cells sense LPS after gut barrier injury to enhance GLP-1 secretion. Cell Reports. 2017;21(5):1160-1168.
12. Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain, Behavior, and Immunity. 2007;21(2):153-160.
13. World Health Organization and UNICEF. Oral rehydration salts: production of the new ORS. WHO/FCH/CAH/06.1. Geneva: WHO; 2006.
14. Hahn S, Kim Y, Garner P. Reduced osmolarity oral rehydration solution for treating dehydration due to diarrhoea in children: systematic review. BMJ. 2001;323(7304):81-85.
15. Dirks ML, Wall BT, van de Valk B, et al. One week of bed rest leads to substantial muscle atrophy and induces whole-body insulin resistance in the absence of skeletal muscle lipid accumulation. Diabetes. 2016;65(10):2862-2875.
16. Kortebein P, Ferrando A, Lombeida J, Wolfe R, Evans WJ. Effect of 10 days of bed rest on skeletal muscle in healthy older adults. JAMA. 2007;297(16):1772-1774.
17. Volkert D, Beck AM, Cederholm T, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clinical Nutrition. 2019;38(1):10-47.
18. McKinley MJ, Martelli D, Pennington GL, Trevaks D, McAllen RM. Divergent efferent pathways for thirst and GLP-1 signalling: implications for the effects of GLP-1 receptor agonists on fluid intake. Frontiers in Endocrinology. 2020;11:606.
19. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60(5):1561-1565.
20. Hall JE, Hall ME. Guyton and Hall Textbook of Medical Physiology. 14th edition. Elsevier; 2021. Chapters on body fluid compartments and regulation of extracellular fluid osmolarity and sodium.